Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Vincristine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 6/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 6/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 6/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 6/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 6/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 6/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 6/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 6/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 6/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 6/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 6/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 6/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 6/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 6/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vincristine SCHEMBL13321219 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Vincristine SCHEMBL13662639 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Vincristine SCHEMBL14177979 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Vincristine SCHEMBL13840950 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Vincristine SCHEMBL4769981 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Vincristine SCHEMBL13300978 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Vincristine SCHEMBL15474330 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Vincristine SCHEMBL18402663 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Vincristine SCHEMBL15866613 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Vincristine SCHEMBL19522762 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 823 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| US-20090163442-A1 | TREATMENT OF CANCER WITH 2-DEOXYGALACTOSE | LANDAU BERNARD R | 2009-06-25 | — | — | US | claimed |
| EP-2049125-A2 | TREATMENT OF CANCER WITH 2-DEOXYGALACTOSE | Landau, Bernard R. (US) | 2009-04-22 | — | — | EP | claimed |
| WO-2007098183-A2 | TREATMENT OF CANCER WITH 2-DEOXYGALACTOSE | LANDAU BERNARD R (US) | 2007-08-30 | — | — | WO | claimed |
| EP-1325324-A4 | IMPROVED ANTI-VIRAL AND ANTI-TUMOR CHEMOTHERAPY BY ADMINISTRATION OF ERYTHROPOEITIN | ORTHO MCNEIL PHARM INC (US) | 2004-11-10 | — | — | EP | claimed |
| EP-1325324-A1 | IMPROVED ANTI-VIRAL AND ANTI-TUMOR CHEMOTHERAPY BY ADMINISTRATION OF ERYTHROPOEITIN | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2003-07-09 | — | — | EP | claimed |
| US-20020052317-A1 | Anti-viral and anti-tumor chemotherapy by administration of erythropoeitin | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-05-02 | — | — | US | claimed |
| WO-2002010743-A1 | IMPROVED ANTI-VIRAL AND ANTI-TUMOR CHEMOTHERAPY BY ADMINISTRATION OF ERYTHROPOEITIN | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-07 | — | — | WO | claimed |
| US-4853221-A | Method for treating non-small cell lung cancer, head and neck cancers and breast cancer | WARNER-LAMBERT COMPANY (US) | 1989-08-01 | — | — | US | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-3808748-B1 | SUBSTITUTED PIPERIDINES AS CXCR4-INHIBITORS | X4 PHARMACEUTICALS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-112839649-B | CXCR4 inhibitor compositions and methods of making and using the same | X4 制药有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260132213-A1 | CLINICALLY PROVEN SUBCUTANEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND THEIR USES IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE | JANSSEN BIOTECH INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-5804568-A | PARENTERAL ADMINISTRATION OF CYTOTOXIC DRUG MIXED WITH ANTIULCERATIVE AMOUNT OF SUBSTITUTED CYCLODEXTRIN; SIDE EFFECT REDUCTION | SUPERGEN, INC. (US) | 1998-09-08 | — | — | US | disclosed |
| US-5602112-A | ANTI-ULCERATION AMOUNT OF SUBSTITUTED CYCLODEXTRIN, CYTOTOXIC ANTICANCER DRUG SOLUBLE IN AQUEOUS SOLUTION, SUGAR ALCOHOL | SUPERGEN, INC. (US) | 1997-02-11 | — | — | US | disclosed |
| EP-0717638-A1 | IMPROVED PHARMACEUTICAL FORMULATION | SUPERGEN, INC. (US) | 1996-06-26 | — | — | EP | disclosed |
| WO-1995006485-A1 | IMPROVED PHARMACEUTICAL FORMULATION | SUPERGEN, INC. (US) | 1995-03-09 | — | — | WO | disclosed |
| US-4923876-A | VINCRISTINE SULFATE, CITRATE BUFFER | CETUS CORPORATION (US) | 1990-05-08 | — | — | US | disclosed |
| US-4853221-A | Method for treating non-small cell lung cancer, head and neck cancers and breast cancer | WARNER-LAMBERT COMPANY (US) | 1989-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132213-A1 | CLINICALLY PROVEN SUBCUTANEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND THEIR USES IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE | CD22, CD38, CD47 | TUBB4A 4684/4885TUBB 4758/4885TUBA3C 4782/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | TUBB4A 1424/4885TUBB 1206/4885TUBA3C 1660/4885 |
| US-20090163442-A1 | TREATMENT OF CANCER WITH 2-DEOXYGALACTOSE | ST6GAL1, B4GALT1, GALK1 | TUBB4A 1692/4885TUBB 1396/4885TUBA3C 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.